HSP90 inhibitors selectively kill cancer cells compared to normal cells, and have also demonstrated antitumor effects towards lymphomas, melanomas, as well as some solid tumors (e.g., breast cancer, non-small-cell lung cancer) (16, 17). Here, HSP90AB1 is linked to cancer.